Patients with acute promyelocytic leukemia (APL) are prone to both bleeding and thrombosis. The bleeding complications are well known. In contrast, APL-associated thrombosis is relatively underappreciated. We aimed to explore the issue of APL-associated thrombosis events. In the past 20 years, 127 cases with APL were found in our hospital database. We collected their coagulation laboratory profiles, including leukemia burdens, white blood cell and platelet counts, prothrombin time, activated partial thromboplastin time, fibrinogen levels, and disseminated intravascular coagulation scores. Data were compared between patients with or without thrombosis. Clinical outcomes and potential risk factors were obtained for analysis. Ten cases with APL-associated thrombosis were found. The incidence of thrombosis was 7.9% in our cohort. Five patients had cerebral infarction, 5 had catheter-related thrombosis and 1 had acute myocardial infarction. No laboratory data were associated with clinical thrombosis. Three patients died during the induction phase but thrombosis was not the direct cause of death for any of them. We conclude that patients with APL are susceptible to thrombosis in addition to bleeding. Laboratory coagulation parameters did not predict thrombosis in our series. Ischemic stroke and catheter-related thrombosis were the most common events in our Taiwanese cohort. Such a thrombosis pattern is unique and worth further investigation.

Keywords:
Acute promyelocytic leukemia, Catheter-related thrombosis, Disseminated intravascular coagulation, Ischemic stroke, Thrombosis
1.
Tallman MS, Abutalib SA, Altman JK: The double hazard of thrombophilia and bleeding in acute promyelocytic leukemia. Semin Thromb Hemost 2007;33:330–338.
2.
Sanz MA, Montesinos P: Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res 2010;125(suppl 2):S51–S54.
3.
Chang H, Kuo MC, Shih LY, Dunn P, Wang PN, Wu JH, Lin TL, Hung YS, Tang TC: Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol 2012;88:321–328.
4.
Cordonnier C, Vernant JP, Brun B, Heilmann MG, Kuentz M, Bierling P, Farcet JP, Rodet M, Duedari N, Imbert M: Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985;55:18–25.
5.
Di BE, Avvisati G, Castaman G, Luce VM, De SV, Rodeghiero F, Mandelli F: Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000;108:689–695.
6.
Yanada M, Matsushita T, Asou N, Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S, Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M, Miyazaki Y, Ohno R, Naoe T: Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome. Eur J Haematol 2007;78:213–219.
7.
Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris MS, Gentilini F, Petti MC, Cimino G, Mandelli F, Lo-Coco F: Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2007;21:79–83.
8.
Rees D, Grimwade D, Langabeer S, Burnett A, Goldstone A: Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. MRC Adult Leukaemia Working Party. Br J Haematol 1997;96:490–492.
9.
Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M: Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327–1330.
10.
DiGiovanni RJ Jr, Crilley P, Kerstein MD: Peripheral arterial occlusion in acute promyelocytic leukemia. Cardiovasc Surg 1999;7:258–260.
11.
Candelpergher G, Suzzi GL, Visona A, Buchberger R: Acute myocardial infarct as the first manifestation of acute myeloid leukemia. Description of an anatomo-clinical case. G Ital Cardiol 1980;10:1403–1407.
12.
Cahill TJ, Chowdhury O, Myerson SG, Ormerod O, Herring N, Grimwade D, Littlewood T, Peniket A: Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: diagnosis and follow-up by cardiac magnetic resonance imaging. Circulation 2011;123:e370–e372.
13.
De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, Zini G, Pagano L, Sica S, Leone G: The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3:1985–1992.
14.
Stansbury JP, Jia H, Williams LS, Vogel WB, Duncan PW: Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes. Stroke 2005;36:374–386.
15.
Feigin V, Carter K, Hackett M, Barber PA, McNaughton H, Dyall L, Chen MH, Anderson C: Ethnic disparities in incidence of stroke subtypes: Auckland Regional Community Stroke Study, 2002–2003. Lancet Neurol 2006;5:130–139.
16.
Hazani A, Weidenfeld Y, Tatarsky I, Bental E: Acute promyelocytic leukemia presenting as sudden blindness and sinus vein thrombosis. Am J Hematol 1988;28:56–57.
17.
Beslow LA, Abend NS, Smith SE: Cerebral sinus venous thrombosis complicated by cerebellar hemorrhage in a child with acute promyelocytic leukemia. J Child Neurol 2009;24:110–114.
18.
Colovic M, Miljic P, Colovic N, Jankovic G, Stojkovic M: Reversible portal vein thrombosis complicating induction therapy of acute promyelocytic leukemia. Thromb Res 2001;101:101–103.
19.
Assouline D, Negrier C, Coguard I, Archimbaud E, Fiere D, Bret M, Bodnar D: Successful systemic thrombolysis of hepatic vein thrombosis in a patient with promyelocytic leukemia treated with all-trans retinoic acid. Am J Hematol 1995;48:291–292.
20.
van Rooden CJ, Rosendaal FR, Barge RM, van Oostayen JA, van der Meer FJ, Meinders AE, Huisman MV: Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003;123:507–512.
21.
Boersma RS, Jie KS, Verbon A, van Pampus EC, Schouten HC: Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 2008;19:433–442.
22.
Boersma RS, Hamulyak K, Cate HT, Schouten HC: Congenital thrombophilia and central venous catheter-related thrombosis in patients with cancer. Clin Appl Thromb Hemost 2010;16:643–649.
23.
Melillo L, Grandone E, Colaizzo D, Cappucci F, Valvano MR, Cascavilla N: Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007;117:215–220.
24.
Dally N, Hoffman R, Haddad N, Sarig G, Rowe JM, Brenner B: Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia – a single center experience in 34 patients. Thromb Res 2005;116:109–114.
25.
Escudier SM, Kantarjian HM, Estey EH: Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymphoma 1996;20:435–439.
26.
Zhao W, Wang H, Wang X, Wu F, Guo W, Qu B, Shen Z, Wang Z: Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res 2001;102:197–204.
27.
Tallman MS, Lefebvre P, Baine RM, Shoji M, Cohen I, Green D, Kwaan HC, Paietta E, Rickles FR: Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia. J Thromb Haemost 2004;2:1341–1350.
28.
Hashimoto S, Koike T, Tatewaki W, Seki Y, Sato N, Azegami T, Tsukada N, Takahashi H, Kimura H, Ueno M: Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994;8:1113–1115.
29.
Brown JE, Olujohungbe A, Chang J, Ryder WD, Morganstern GR, Chopra R, Scarffe JH: All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol 2000;110:1010–1012.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.